STOCK TITAN

United Therapeutics Corporation To Present At The 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

United Therapeutics Corporation (Nasdaq: UTHR) announced that CEO Martine Rothblatt will present at the 39th J.P. Morgan Healthcare Conference on January 11, 2021. The presentation, focusing on the company's business updates, will be held virtually from 10:50 a.m. to 11:30 a.m. EST. Interested parties can access the live webcast through the company's website, with an archived version available 24 hours post-event for 30 days.

United Therapeutics aims to tackle organ shortages through innovative technologies.

Positive
  • None.
Negative
  • None.

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 4, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business during a presentation and question and answer session at the 39th annual J.P. Morgan Healthcare Conference.

The presentation will take place virtually on Monday, January 11, 2021, from 10:50 a.m. to 11:30 a.m., Eastern Standard Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the presentation will be available approximately 24 hours after the session ends and can be accessed at the same location for 30 days.

About United Therapeutics

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment, and society – will sustain our success in the long term.

Through our wholly owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements relating to our ability to create value and sustain our success in the long-term, as well as our efforts to develop technologies that either delay the need for transplantable organs or expand the supply of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of January 4, 2021 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.

For Further Information Contact:
Dewey Steadman at (202) 919-4097
Email: ir@unither.com 

 

Cision View original content:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301199663.html

SOURCE United Therapeutics Corporation

FAQ

When is United Therapeutics presenting at the J.P. Morgan Healthcare Conference?

United Therapeutics will present on January 11, 2021, from 10:50 a.m. to 11:30 a.m. EST.

Who is presenting for United Therapeutics at the conference?

CEO Martine Rothblatt will present an overview of the company's business.

How can I access the United Therapeutics presentation?

The presentation can be accessed via a live webcast on United Therapeutics' website.

What is the focus of United Therapeutics at the J.P. Morgan Conference?

The focus will be on providing updates and an overview of the company's business.

What technologies is United Therapeutics working on?

United Therapeutics is focused on technologies to address the national shortage of transplantable organs.

United Therapeutics Corp

NASDAQ:UTHR

UTHR Rankings

UTHR Latest News

UTHR Stock Data

16.11B
43.82M
1.85%
100.24%
4.96%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SILVER SPRING